Multiple Myeloma

  • Final analysis of survival outcomes in the randomized phase 3 FIRST trial
    Thierry Facon, Meletios A. Dimopoulos, Angela Dispenzieri, John V. Catalano, Andrew Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie D. Cavenagh, Catarina Geraldes, Je-Jung Lee, Christine Chen, Albert Oriol, Javier De La Rubia, Darell White, Daniel Binder, Jin Lu, Kenneth C. Anderson, Philippe Moreau, Michel Attal, Aurore Perrot, Bertrand Arnulf, Lugui Qiu, Murielle Roussel, Eileen Boyle, Salomon Manier, Mohamad Mohty, Herve Avet-Loiseau, Xavier Leleu, Annette Ervin-Haynes, Guang Chen, Vanessa Houck, Lotfi Benboubker and Cyrille Hulin
  • Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
    Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, Thierry Facon, Martine Amiot, Philippe Moreau, Elizabeth A. Punnoose, Stefanie Alzate, Martin Dunbar, Tu Xu, Suresh K. Agarwal, Sari Heitner Enschede, Joel D. Leverson, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo and Cyrille Touzeau
  • Neutral tumor evolution in myeloma is associated with poor prognosis
    David C. Johnson, Oleg Lenive, Jonathan Mitchell, Graham Jackson, Roger Owen, Mark Drayson, Gordon Cook, John R. Jones, Charlotte Pawlyn, Faith E. Davies, Brian A. Walker, Christopher Wardell, Walter M. Gregory, David Cairns, Gareth J. Morgan, Richard S. Houlston and Martin F. Kaiser
  • How I treat myeloma with new agents
    Philippe Moreau
  • Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
    Yi L. Hwa, Rahma Warsame, Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy, Shaji K. Kumar, David Dingli, Steve R. Zeldenrust, Nelson Leung, Susanne R. Hayman, Prashant Kapoor, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Stephen Russell, Ronald S. Go, Miriam A. Hobbs, Amie L. Fonder, S. Vincent Rajkumar and Angela Dispenzieri
  • “Hof” in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma
    Beenu Thakral and Sa A. Wang
  • Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Ashraf Badros, Elizabeth Hyjek, Ning Ma, Alexander Lesokhin, Ahmet Dogan, Aaron P. Rapoport, Mehmet Kocoglu, Emily Lederer, Sunita Philip, Todd Milliron, Cameron Dell, Olga Goloubeva and Zeba Singh
  • Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Jonas Paludo, Joseph R. Mikhael, Betsy R. LaPlant, Alese E. Halvorson, Shaji Kumar, Morie A. Gertz, Suzanne R. Hayman, Francis K. Buadi, Angela Dispenzieri, John A. Lust, Prashant Kapoor, Nelson Leung, Stephen J. Russell, David Dingli, Ronald S. Go, Yi Lin, Wilson I. Gonsalves, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, Taimur Sher, Asher A. Chanan-Khan, Sikander Ailawadhi, A. Keith Stewart, Craig B. Reeder, Paul G. Richardson, S. Vincent Rajkumar and Martha Q. Lacy
  • Coexistence of multiple myeloma and Paget disease of bone
    Maryam Pourabdollah and Hong Chang
  • Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/ refractory MM
    Philippe Moreau, Asher Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, Elizabeth A. Punnoose, Jaclyn Cordero, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Kevin J. Freise, Joel D. Leverson, Sari Heitner Enschede, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo and Simon J. Harrison